Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.61 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.55 |
| ▸ | IDO1 | P14902 | 4/20 | 0.53 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.47 |
| ▸ | CES1 | P23141 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2850348 | 0.91 | TSHR (0.59) | TSHRLOXL2IDO1KCNJ1KCNH2 | |
| SCHEMBL6821944 | 0.89 | TSHR (0.58) | TSHRLOXL2IDO1KCNJ1KCNH2 | |
| Nitrobenzene SCHEMBL29050944 | 0.88 | ALDH1A1 (0.56) | ALDH1A1LMNAGAAMAPTKMT2A | |
| SCHEMBL30122708 | 0.87 | MAPT (0.65) | ALDH1A1MAPTKMT2AMEN1 | |
| SCHEMBL7999122 | 0.85 | TSHR (0.66) | TSHRLOXL2IDO1KCNJ1KCNH2 | |
| SCHEMBL4833242 | 0.84 | TSHR (0.59) | TSHRLOXL2IDO1KCNJ1KCNH2 | |
| SCHEMBL350869 | 0.83 | TSHR (0.63) | TSHRLOXL2KCNJ1KCNH2ALDH1A1 | |
| SCHEMBL1302992 | 0.81 | TSHR (0.61) | TSHRLOXL2IDO1KCNJ1KCNH2 | |
| SCHEMBL7733616 | 0.81 | TSHR (0.61) | TSHRLOXL2IDO1KCNJ1KCNH2 | |
| SCHEMBL15074911 | 0.81 | TSHR (0.61) | TSHRLOXL2KCNJ1KCNH2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114539158-B | FXIa inhibitor compound and preparation method and application thereof | 沈阳药科大学 | 2023-12-08 | — | — | CN | claimed |
| CN-114539158-A | FXIa inhibitor compound and preparation method and application thereof | 沈阳药科大学 | 2022-05-27 | — | — | CN | claimed |
| CN-1353609-B | Amide substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES CO | 2011-07-13 | — | — | CN | claimed |
| CN-1353609-A | Amide substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES CO (US) | 2002-06-12 | — | — | CN | claimed |
| US-20240398776-A1 | INHIBITORS OF TGF-BETA R1 (ALK5) USEFUL TO TREAT CELL PROLIFERATION DISORDERS | NEXYS THERAPEUTICS, INC. (US) | 2024-12-05 | — | — | US | disclosed |
| US-12102626-B2 | (Pyridin-2-yl)amine derivatives as TGF-BETA R1 (ALK5) inhibitors for the treatment of cancer | NEXYS THERAPEUTICS, INC. (US) | 2024-10-01 | — | — | US | disclosed |
| EP-3902796-B1 | (PYRIDIN-2-YL)AMINE DERIVATIVES AS TGF-BETA R1 (ALK5) INHIBITORS FOR THE TREATMENT OF CANCER | NEXYS THERAPEUTICS INC (US) | 2024-02-07 | — | — | EP | disclosed |
| CN-114539158-B | FXIa inhibitor compound and preparation method and application thereof | 沈阳药科大学 | 2023-12-08 | — | — | CN | disclosed |
| US-11708367-B2 | Compounds for the treatment of kinase-dependent disorders | EXELIXIS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-11678968-B2 | Urological device including a valve retained in a urinary catheter | COLOPLAST A/S (DK) | 2023-06-20 | — | — | US | disclosed |
| CN-115697415-A | Techniques for preventing or treating infections | 拜尔哈文制药股份有限公司 | 2023-02-03 | — | — | CN | disclosed |
| US-20220340983-A1 | SYSTEMS AND ASSAYS FOR IDENTIFYING PU.1 INHIBITORS | MASSACHUSTTS INSTITUTE OF TECHNOLOGY (US) | 2022-10-27 | — | — | US | disclosed |
| US-5861535-A | Reductive alkylation process to prepare tertiary aminoaryl compounds | EASTMAN KODAK COMPANY (US) | 1999-01-19 | — | — | US | disclosed |
| EP-0369627-B1 | Pyrimidinedione derivative compounds, method of producing the same and antiarrythmic agents containing the same | MITSUI TOATSU CHEMICALS (JP) | 1994-12-21 | — | — | EP | disclosed |
| EP-0542867-A4 | METHODS OF PREVENTING OR DECREASING TISSUE DAMAGE BY NOVEL ANTIOXIDANTS AND FREE RADICAL SCAVENGERS | — | 1993-07-28 | — | — | EP | disclosed |
| EP-0542867-A1 | METHODS OF PREVENTING OR DECREASING TISSUE DAMAGE BY NOVEL ANTIOXIDANTS AND FREE RADICAL SCAVENGERS | GENSIA, INC. (US) | 1993-05-26 | — | — | EP | disclosed |
| US-5008267-A | Pyrimidinedione compounds, method of producing the same and antiarrythmic agents containing the same | MITSUI TOATSU CHEMICALS, INCORPORATED (JP) | 1991-04-16 | — | — | US | disclosed |
| CN-1011784-B | Process for preparing antiallergic and antimuscotromospasm agents N-benzhydryldiazacycloalkylalkyl anilides | RECKORDATY CHEMICALS CORP (CH) | 1991-02-27 | — | — | CN | disclosed |
| EP-0369627-A2 | Pyrimidinedione derivative compounds, method of producing the same and antiarrythmic agents containing the same | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1990-05-23 | — | — | EP | disclosed |
| CN-86105641-A | The method for preparing antianaphylaxis and antibronchospasm of N-dibenzyl-diazacyclo alkyl-alkyl-anilide | — | 1987-04-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12102626-B2 | (Pyridin-2-yl)amine derivatives as TGF-BETA R1 (ALK5) inhibitors for the treatment of cancer | TGFBR1, TGFBR2, ACVR1 | TSHR 541/4885LOXL2 159/4885IDO1 191/4885 |
| US-11708367-B2 | Compounds for the treatment of kinase-dependent disorders | ERBB2, ERBB3, MAP3K6 | TSHR 873/4885LOXL2 1041/4885IDO1 3303/4885 |
| US-20220340983-A1 | SYSTEMS AND ASSAYS FOR IDENTIFYING PU.1 INHIBITORS | PMP22, MAG, CREBBP | TSHR 4526/4885LOXL2 3228/4885IDO1 1485/4885 |
| US-20240398776-A1 | INHIBITORS OF TGF-BETA R1 (ALK5) USEFUL TO TREAT CELL PROLIFERATION DISORDERS | ACVR1, TGFBR1, ACVRL1 | TSHR 581/4885LOXL2 194/4885IDO1 1185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.